Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity-Reference-Cited by-同舟云学术

Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity

Published:2017-06-01 Issue:6 Volume:135 Page:654
ISSN:2168-6165
Container-title:JAMA Ophthalmology
language:en
Short-container-title:JAMA Ophthalmol

Author:

Wallace David K.¹,Kraker Raymond T.²,Freedman Sharon F.¹,Crouch Eric R.³,Hutchinson Amy K.⁴,Bhatt Amit R.⁵,Rogers David L.⁶,Yang Michael B.⁷,Haider Kathryn M.⁸,VanderVeen Deborah K.⁹,Siatkowski R. Michael¹⁰,Dean Trevano W.²,Beck Roy W.²,Repka Michael X.¹¹,Smith Lois E.⁹,Good William V.¹²,Hartnett Mary Elizabeth¹³,Kong Lingkun¹⁴,Holmes Jonathan M.¹⁵,

Affiliation:

1. Duke Eye Center, Durham, North Carolina

2. Jaeb Center for Health Research, Tampa, Florida

3. Eastern Virginia Medical School, Norfolk

4. Emory University School of Medicine, Atlanta, Georgia

5. Texas Children’s Hospital, Houston

6. Pediatric Ophthalmology Associates Inc, Columbus, Ohio

7. Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio

8. Riley Hospital for Children, Indianapolis, Indiana

9. Boston Children’s Hospital, Boston, Massachusetts

10. Dean McGee Eye Institute, University of Oklahoma, Oklahoma City

11. Wilmer Eye Institute, Baltimore, Maryland